{"id":"W3026866758","doi":"10.1016/j.annonc.2020.03.241","title":"140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Genentech; PharmaMar; Eisai; Daiichi-Sankyo; Invitae; Puma Biotechnology; Incyte; BeiGene; AbbVie; Daiichi Sankyo Europe; U.S. Department of Defense; Sanofi; Cilag; Celldex Therapeutics; Amgen; Vifor Pharma; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Carboplatin; Veliparib; Breast cancer; Hazard ratio; Metastatic breast cancer; Oncology; Population; Triple-negative breast cancer; Progression-free survival; Cancer; Chemotherapy; Confidence interval; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004432057,0.0005385271,0.001788774,0.0001655146,0.0001102421,0.00001632063,0.0002495755,0.000240391,0.00008562395],"category_scores_gemma":[0.0006251765,0.0004036097,0.0001177062,0.001123948,0.0006872446,0.0003879961,0.0001132955,0.0008857581,0.000002647691],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008422974,"about_ca_system_score_gemma":0.00103865,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02005091,"about_ca_topic_score_gemma":0.009541632,"domain_scores_codex":[0.9959103,0.000707483,0.001207899,0.0008793417,0.0005757448,0.0007192596],"domain_scores_gemma":[0.9958312,0.001590498,0.00120421,0.0002980686,0.0007613464,0.000314693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7957472,0.002103281,0.01645732,0.00004313749,0.001297454,0.00007172878,0.02684239,0.0004677302,0.000752366,0.00002375986,0.0007627219,0.1554309],"study_design_scores_gemma":[0.4081727,0.01054374,0.5737582,0.0007537416,0.0002495481,0.000009203432,0.004399848,0.0002755639,0.0008364144,0.0002779926,0.0002597113,0.0004633259],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9618072,0.001508345,0.00002819421,0.0228613,0.0001950041,0.002951476,0.01047583,0.0000386819,0.000133948],"genre_scores_gemma":[0.9943448,0.001180411,0.0003590753,0.002984802,0.0002443276,0.0004664984,0.0003158161,0.00006903645,0.00003526559],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5573009,"threshold_uncertainty_score":0.9998416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03757875422880337,"score_gpt":0.347691989660081,"score_spread":0.3101132354312776,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}